Document is current
Any future updates will be listed below
-
Authors
Laing, Kerry J. https://orcid.org/0000-0001-9245-5325
Ouwendijk, Werner J. D. https://orcid.org/0000-0001-8393-296X
Campbell, Victoria L. https://orcid.org/0000-0001-6490-5974
McClurkan, Christopher L.
Mortazavi, Shahin
Elder Waters, Michael
Krist, Maxwell P.
Tu, Richard
Nguyen, Nhi
Basu, Krithi
Miao, Congrong
Schmid, D. Scott
Johnston, Christine
Verjans, Georges M. G. M. https://orcid.org/0000-0002-2465-2674
Koelle, David M.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG064800)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400049C, 75N93019C00063)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 1 June 2022
Accepted: 27 October 2022
First Online: 15 November 2022
Competing interests
: D.M.K. and K.J.L. are scientific advisors or consultants for Curevo and MaxHealth concerning candidate vaccines for herpes zoster. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Diseases Control and Prevention (CDC). The remaining authors declare no competing interests.
